Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional
Yohan Suryo Rahmanto1, Wenjing Shen2, Xu Shi3
1Sidney Kimmel Comprehensive Cancer Center and Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, 21205, USA. suryoysr@gmail.com.
Abstract:
Somatic inactivating mutations of ARID1A, a SWI/SNF chromatin remodeling gene, are prevalent in human endometrium-related malignancies. To elucidate the mechanisms underlying how ARID1A deleterious mutation contributes to tumorigenesis, we establish genetically engineered murine models with Arid1a and/or Pten conditional deletion in the endometrium. Transcriptomic analyses on endometrial cancers and precursors derived from these mouse models show a close resemblance to human uterine endometrioid carcinomas. We identify transcriptional networks that are controlled by Arid1a and have an impact on endometrial tumor development. To verify findings from the murine models, we analyze ARID1AWT and ARID1AKO human endometrial epithelial cells. Using a system biology approach and functional studies, we demonstrate that ARID1A-deficiency lead to loss of TGF-β tumor suppressive function and that inactivation of ARID1A/TGF-β axis promotes migration and invasion of PTEN-deleted endometrial tumor cells. These findings provide molecular insights into how ARID1A inactivation accelerates endometrial tumor progression and dissemination, the major causes of cancer mortality.
Insights
Loss of ARID1A in endometrial cells disrupts tumor suppression, promoting cancer progression and spread. This study reveals how ARID1A inactivation accelerates uterine endometrioid carcinoma development.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Somatic inactivating mutations in ARID1A, a SWI/SNF chromatin remodeling gene, are common in endometrial cancers.
- Understanding ARID1A's role in tumorigenesis is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the mechanisms by which ARID1A mutations contribute to endometrial cancer development and progression.
- To identify molecular pathways affected by ARID1A inactivation in endometrial malignancies.
Main Methods:
- Generation of genetically engineered mouse models with conditional deletion of Arid1a and/or Pten in the endometrium.
- Transcriptomic analysis of murine endometrial cancers and precursors.
- Functional studies and systems biology approach using human endometrial epithelial cells (ARID1A wild-type and knockout).
Main Results:
- Murine models recapitulated key features of human uterine endometrioid carcinomas.
- Identified transcriptional networks regulated by Arid1a influencing endometrial tumor development.
- Demonstrated that ARID1A deficiency leads to loss of TGF-β tumor suppressive function.
- Showed ARID1A/TGF-β axis inactivation promotes migration and invasion in PTEN-deleted endometrial tumor cells.
Conclusions:
- ARID1A inactivation accelerates endometrial tumor progression and dissemination.
- Loss of ARID1A function impairs TGF-β tumor suppressive activity.
- Findings provide molecular insights into endometrial cancer pathogenesis, highlighting the ARID1A/TGF-β axis.
Related Concept Videos
Abnormal Proliferation
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Non-LTR Retrotransposons
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...


